LIGHTNING RELEASES – Vernon Hills, IL, February 5, 2014. Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the USPTO has issued U.S. Patent No. 8,604,047 entitled “Method and Composition for Treating Nodulocystic and Conglobate Acne Vulgaris.” This patent provides for once-weekly oral administration of selective inhibitors of type 1 and/or type 2 isoforms of steroid 5α-reductase to patients with nodulocystic and conglobate acne vulgaris. These are the most severe types of acne vulgaris, affecting some 8-10 million patients in the United States and producing scarring and substantial functional disability as a result of the scars.
“We are very pleased to receive the patent on this potential major medical advance,” said Jeffrey Bernstein, Ph.D., President & Chief Executive Officer. “We believe our product has many advantages over existing therapies for nodulocystic or conglobate acne.”
Elorac plans to initiate a Phase II double-blind clinical trial of its once-weekly high dose finasteride tablet within the next 12 months.
About Elorac, Inc.
Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the development and commercialization of novel products for dermatology, allergy and oncology. The Company markets dermatological products in the United States through its own dedicated sales force. Elorac has a robust pipeline of products in development, including naloxone lotion for treatment of pruritus accompanying cutaneous T-cell lymphoma, a product that has received orphan drug and fast-track designations from the U.S. Food and Drug Administration, and cidoxepin, the most potent histamine antagonist ever discovered for chronic urticarial. According to Inc. magazine’s 2013 list of fastest-growing private U.S. companies, Elorac ranked 23rd among health-care companies and No. 1 among pharmaceutical companies.
Barry Hollingsworth, Chief Financial Officer
847-362-8200 ext. 230 Direct